Considering that HRS9432 is not metabolized by CYP450 enzymes and exhibits minimal inhibition or induction effects on most CYP metabolic enzymes, we postulate that the drug may trigger hypersensitivity or immune reactions, leading to systemic inflammatory responses or autoimmune hepatitis, consequently resulting in mild elevation of transaminases. The gene discussed is PPIG; the disease is autoimmune hepatitis.